Compare Moderna, Inc. (MRNA) vs Oracle Corporation (ORCL) Price & Performance

Moderna, Inc.Trade

Oracle CorporationTrade

Price performance (Past 24H)

Key statistics

Moderna, Inc. vs Oracle Corporation — how do they compare? Moderna, Inc. trades at $59.66 (market cap $23.60B), while Oracle Corporation trades at $127.83 (market cap $349.63B). The key difference: Oracle Corporation is far larger — about 14.8× Moderna, Inc.'s market cap, and Oracle Corporation pays a 1.65% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.

	MRNA	ORCL
Market Cap	$23.60B	$349.63B
Sector	Health	Technology
52-Week High	$81.80	$328.33
52-Week Low	$22.36	$121.37
Enterprise Value	$19.70B	$478.88B
Dividend Yield	—	1.65%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Moderna, Inc.

Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.

Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.

Oracle Corporation

Oracle (ORCL) trades at $126.48, up 1.78% today, with a strong fundamental backdrop including revenue growth to $57.40B in 2025 and a net income margin of 25.37%. Recent quarters have consistently beaten EPS estimates, and analyst consensus is bullish with a $253.30 price target. Technicals show a bearish overall signal but with bullish oscillators, and the stock faces support near $125.

The outlook is positive given Oracle's AI infrastructure expansion and earnings momentum, but risks include high debt levels and competitive pressures. The stock offers growth potential if execution continues, yet investors should weigh valuation multiples against sector peers.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRNA

ARKG and GNOM ETFs offer different genomic bets with varied risk and returns in 2026.24/7 Wall Street · 15 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral View details →

ORCL

Oracle shares hit key support and show oversold signs, hinting at a possible rebound soon.FXEmpire · 7 hours agoBullish Big tech's hidden debt hits $1.65T, raising investor risk amid AI investment surge.Finbold · 19 hours agoBearish Oracle shifts to AI hyperscale, faces credit downgrade but shows strong growth potential.Stuart Mooney · 1 day agoNeutral View details →

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

About Oracle Corporation

Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.